Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.64 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.62 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.62 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.58 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.55 |
| ▸ | KRAS | P01116 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17586739 | 0.93 | NT5E (0.69) | NT5ETAS1R3TAS1R1TGM2IMPDH2 | |
| SCHEMBL2315645 | 0.93 | NT5E (0.69) | NT5ETAS1R3TAS1R1TGM2IMPDH2 | |
| SCHEMBL2315499 | 0.93 | NT5E (0.69) | NT5ETAS1R3TAS1R1TGM2IMPDH2 | |
| SCHEMBL23176396 | 0.91 | TAS1R3 (0.57) | NT5ETAS1R3TAS1R1TGM2IMPDH2 | |
| SCHEMBL29258512 | 0.87 | NT5E (0.69) | NT5ETAS1R3TAS1R1TGM2IMPDH2 | |
| SCHEMBL2218829 | 0.87 | HPGD (0.57) | NT5ETAS1R3TAS1R1TGM2IMPDH2 | |
| SCHEMBL23149828 | 0.87 | NT5E (0.55) | NT5ETAS1R3TAS1R1TGM2IMPDH2 | |
| SCHEMBL888070 | 0.87 | HPGD (0.57) | NT5ETAS1R3TAS1R1TGM2IMPDH2 | |
| SCHEMBL17438077 | 0.87 | HPGD (0.57) | NT5ETAS1R3TAS1R1TGM2IMPDH2 | |
| E626 SCHEMBL20677331 | 0.87 | NT5E (0.83) | NT5ETAS1R3TAS1R1TGM2IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009997-A1 | METHOD OF TREATING A METABOLIC OR NEUROPSYCHIARTY DISORDER WITH A BH4 DERIVATIVE PRODRUG | BIOMARIN PHARMACEUTICAL INC. (US) | 2010-01-14 | — | — | US | claimed |
| EP-4605523-A1 | OLIGONUCLEOTIDES AND METHODS FOR CAPTURING SINGLE-STRANDED TEMPLATES AND/OR TEMPLATES WITH 3' OVERHANGS | Foundation Medicine, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024137316-A1 | OLIGONUCLEOTIDES AND METHODS FOR CAPTURING SINGLE-STRANDED TEMPLATES AND/OR TEMPLATES WITH 3' OVERHANGS | FOUNDATION MEDICINE, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009997-A1 | METHOD OF TREATING A METABOLIC OR NEUROPSYCHIARTY DISORDER WITH A BH4 DERIVATIVE PRODRUG | PAH, HSD17B4, UGT1A4 | NT5E 3440/4885TAS1R3 3075/4885TAS1R1 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.